University of Regensburg
Also known as: Berthold Langguth, MD, Ph.D. | Department of Neurology, University of Regensburg | Department of Obstetrics and Gynaecology, University of Regensburg, Germany | Department of Surgery, University Medical Center Regensburg | Dept. of Ophthalmology, University of Regensburg | Donauspital KH SMZ Ost, Neurologie | Edward Geissler | Institue for Medical Microbiology, University of Regensburg | Prof. Dr. Berthold Schalke | Psychosoziale Begleitung - Praxis Boniakowski, Regensburg | Regensburg University | Regensburg University Hospital | Regensburg University Hospital Department of Surgery | Regensburg University Hospital, Department of Surgery | Regensburg University Medical Center, Department of Surgery | Regensburg University Medical Center, Director of Surgical Department | Regensburg University Medical Center, Head of Experimental Surgery | Universitat Regensburg | Universitätsklinikum Regensburg | University Hospital of Regensburg | University Hospital Regensburg | University Hospital Regensburg, University of Regensburg | University of Regensburg | University of Regensburg, Department of Pediatric Hematology and Oncology | University of Regensburg, Dept. of Neurology, Germany
Highest phase reached
Phase 4
First clinical trial
Jul 1, 2002Last known activity
Nov 30, 2024
Timeline
1960s
- Jan 1, 1962
University of Regensburg— Founded
Drugs by trial phase (71 distinct, 52 trials)
Phase 4 (5 own, 0 via acquisition)
Phase 3 (27 own, 0 via acquisition)
Phase 2 (33 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Studied for
- Anemia, Aplastic
- Anemia, Sickle Cell
- Astrocytoma
- Atrophic Vaginitis
- Atrophy
- Bronchiolitis
- Bronchiolitis Obliterans
- Carcinoma
- Carcinoma, Hepatocellular
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Colorectal Neoplasms
- Communicable Diseases
- Diabetes Mellitus, Type 2
- Disease
- Dyslipidemias
- End Stage Liver Disease
- Gastritis
- Glioblastoma
- Helicobacter Infections
- Hodgkin Disease
- Hypertrophy
- Infections
- Inflammation
- Keratosis
- Keratosis, Actinic
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Liver Diseases
- Liver Neoplasms
- Lung Neoplasms
- Lymphoma
- Medulloblastoma
- Melanoma
- Metabolic Syndrome
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Neuroblastoma
- Opioid-Related Disorders
- Osteoarthritis, Hip
- Pancreatic Neoplasms
- Parkinson Disease
- Peritoneal Neoplasms
- Pinealoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Renal Insufficiency
- Schizophrenia
- Sickle Cell Trait
- Syndrome
- Thymoma
- Thymus Neoplasms
- Vaginitis
Recent trials (50)
- NCT06137378CollaboratorPhase 2Nov 30, 2024
- NCT06268769Sponsor investigatorPhase 4Mar 9, 2024
- NCT06268769OfficialPhase 4Mar 9, 2024
- NCT06268769Lead sponsorPhase 4Mar 9, 2024
- NCT05880524CollaboratorPhase 2Dec 31, 2023
- NCT06830421CollaboratorPhase 3Aug 9, 2023
- NCT05820841CollaboratorPhase 3Jun 7, 2023
- NCT04720326Sponsor investigatorPhase 4Dec 23, 2020
- NCT04720326Overall official - principal investigatorPhase 4Dec 23, 2020
- NCT04720326Lead sponsorPhase 4Dec 23, 2020
- NCT04201210Reponsible party - principal investigatorPhase 2Apr 1, 2020
- NCT04201210Overall official - principal investigatorPhase 2Apr 1, 2020
- NCT04201210Lead sponsorPhase 2Apr 1, 2020
- NCT04225390CollaboratorPhase 2Jan 31, 2020
- NCT03867617CollaboratorPhase 1/Phase 2Apr 30, 2019
Details
- Founded
- Regensburg, DE Jan 1, 1962
- Last known activity
- Nov 30, 2024